18 results
6-K
CMMB
Chemomab Therapeutics Ltd
5 Nov 12
Current report (foreign)
12:00am
are reached); (ii) acting to recruit an international partner in order to continue developing BC-819 for this indication with a Phase III clinical trial
S-4
EX-10.5
CMMB
Chemomab Therapeutics Ltd
13 Jan 21
Registration of securities issued in business combination transactions
9:30am
with or similar to Company's Business; (ii) employ or otherwise engage, recruit or otherwise solicit, induce or influence any person to leave the employment
8-K/A
CMMB
Chemomab Therapeutics Ltd
14 Apr 21
UNAUDITED PRO FORMA Condensed COMBINED FINANCIAL STATEMENTS
11:50am
and aims to recruit 40 patients with confirmed NASH and fibrosis without cirrhosis, liver fat content 10% and at least one associated risk factor … to recruit clinical study investigators with the appropriate competencies and experience;
- 43 -
clinicians’ and patients’ perceptions
6-K
CMMB
Chemomab Therapeutics Ltd
26 Dec 12
Current report (foreign)
12:00am
to market (if and when these stages are reached); (ii) acting to recruit an international partner in order to continue developing BC-819
S-4/A
wb1s odi4b64g26gw
10 Feb 21
Registration of securities issued in business combination transactions (amended)
1:19pm
424B3
wdnd0 7hz74tsen75
12 Feb 21
Prospectus supplement
12:05pm
S-4
jpn3vzuh ipmt582qx7d
13 Jan 21
Registration of securities issued in business combination transactions
9:30am
DRS
eisp1b7 yvh6z
28 Sep 18
Draft registration statement
12:00am
DRS/A
z7ih6 xh8jkk
27 Nov 18
Draft registration statement (amended)
12:00am
424B4
84ws53ikyks9 lydgr2
13 Feb 19
Prospectus supplement with pricing info
8:20am
F-1
qck rtgcxtt3k
7 Jan 19
Registration statement (foreign)
5:11pm
F-1/A
c5oe0phsz lnm
31 Jan 19
Registration statement (foreign) (amended)
12:00am
F-1/A
9eynvep
11 Feb 19
Registration statement (foreign) (amended)
9:52am
F-1/A
4p5 ot472rb
8 Feb 19
Registration statement (foreign) (amended)
12:00am
20-F/A
l1hx6yj
24 Apr 19
Annual report (foreign) (amended)
5:19pm
- Prev
- 1
- Next